Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation.

Abstract

Congenital erythropoietic porphyria (CEP), which is the result of a deficiency of uroporphyrinogen (URO) III synthase activity, is the most disfiguring porphyria in humans. Various methods of treatment have been used to treat CEP with varying success, including erythrocyte transfusion, hydroxyurea, and splenectomy. The only treatment that corrects the enzymatic defect resulting in a cure is bone marrow/stem cell transplantation, which has been reported previously in only 5 patients worldwide. We describe the first patient with CEP who underwent successful bone marrow transplantation performed in the United States and review the therapeutic options in the management of this challenging type of porphyria.

• Authors: F A Harada, T A Shwayder, R J Desnick, H W Lim
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 45 Issue 2 Pg. 279-82 (Aug 2001) ISSN: 0190-9622 [Print] United States
• PMID: 11464191 (Publication Type: Case Reports, Journal Article)

Topics

• Bone Marrow Transplantation
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Infant
• Porphyria, Erythropoietic (diagnosis, therapy)